Teva Agrees To End IP Suit Over Aricept Patent

Law360, New York (July 20, 2010, 5:26 PM EDT) -- Generics maker Teva Pharmaceuticals USA Inc. has agreed to suspend litigation over a compound patent for Eisai Co. Ltd.'s popular Alzheimer's drug Aricept, effectively ending Teva's bid to manufacture a generic version of the drug before the patent expires in November.

Judge Garrett E. Brown Jr. of the U.S. District Court for the District of New Jersey signed off on the agreement Monday, calling for the case to be dismissed after the patent expires. Remaining in effect is a March 2008 preliminary injunction prohibiting Teva from...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.